

## AMENDMENT TO THE SPECIFICATION

On page 36, in Table 2, please insert the following SEQ ID NOS.

**Table 1: Primer and probe sequences used for the real-time quantitative PCR analysis**

<b>Gene description</b>	<b>Primer name</b>	<b>primer sequence</b>
Kidney injury molecule 1 (KIM-1)	rKIM1.forward	5'- CAC TCC ACT TCT GTC TTG ATG CTC -3' (SEQ ID NO: 1)
	rKIM1.reverse	5'- GCA CGT CTC CTC CCT GCA -3' (SEQ ID NO: 2)
	rKIM1.probe	FAM5'- TGT TCC TAA ACT CAC CCA CTG AGC TCT GAA TT -3'TAMRA (SEQ ID NO: 3)
Calbindin-D28k	rCABP28.forward	5'-ACA CTG TTG GTT CAA GCT GGC-3' (SEQ ID NO: 4)
	rCABP28.reverse	5'-CTT GGA AAT ATA GGC ATA GTA TCA GAC AGA T-3' (SEQ ID NO: 5)
	rCABP28.probe	FAM5'-TGG TGG CAA GGG AAG GTA GCC AGA-3'TAMRA (SEQ ID NO: 6)
Osteopontin	rOSTEO.forward	5'-GAC AGT CAG GCG AGT TCC AAA-3' (SEQ ID NO: 7)
	rOSTEO.reverse	5'- CTT GTC CTC ATG GCT GTG AAA C -3' (SEQ ID NO: 8)
	rOSTEO.probe	FAM5'- CCA GCC TGG AAC ATC AGA GCC ACG -3'TAMRA (SEQ ID NO: 9)
Epidermal growth factor precursor	rEGFp.forward	5'- GCA CGA CAT CAC TGT GGT GTC -3' (SEQ ID NO: 10)
	rEGFp.reverse	5'- ATC CCC AAG AGG AGC AGC A -3' (SEQ ID NO: 11)
	rEGFp.probe	FAM5'- TCT GTG TGG TGG CGC TGG CC -3'TAMRA (SEQ ID NO: 12)
Clusterin	rTRPM2.forward	5'- AAG GAG GGA ATC TCC CAG CTT -3' (SEQ ID NO: 13)
	rTRPM2.reverse	5'- GCG CTG GAG ACA TGT GGA GT-3' (SEQ ID NO: 14)
	rTRPM2.probe	FAM5'- CCG AGG TTG CTG CAG ACC CCT AGA-3'TAMRA (SEQ ID NO: 15)
Alpha-2u (Lipocalin 2)	rLPC2.forward	5'- GGT CGG TGG GAA CAG AGA AA-3' (SEQ ID NO: 16)
	rLPC2.reverse	5'- AAG GAG CGA TTC GTC AGC TTT-3'(SEQ ID NO: 17)
	rLPC2.probe	FAM5'- TGT TGT TAT CCT TGA GGC CCA GAG ACT TGG-3'TAMRA (SEQ ID NO: 18)

On page 38, in Table 4, please insert the following SEQ ID NOS.

Table 4: Primer and probe sequences used for the real-time quantitative PCR analysis

Podocin	rPODO.forward	5'-CACTCTTCAGTCCTTGTCCACAGA-3' (SEQ ID NO: 19)
	rPODO.reverse	5'- AAGGTTCAGCATGTCAAAGGGTAA-3' (SEQ ID NO: 20)
	rPODO.probe	FAM5'-AGCCGTCCACCGTGGTTTTGCC-3'TAMRA (SEQ ID NO: 21)